Digital pathology is a digital version of conventional pathological tests and labs. The digitalization facilitates better workflow efficiency; accurate analysis with minimal error rate. A single digital pathological test instrument operated by a single pathologist can accomplish tests that were formerly done, using five conventional pathological instruments.
The digital pathology systems are getting very popular worldwide, which is attributed mainly to its capability to efficiently recognize and validate new drug candidates, create molecular treatments, and measure toxicology in the new drug, and classify patients for the treatment. Whole slide imaging (WSI) is the most widely adopted technology for the digital pathology, attributed to its advantages such as Z-axis scanning of the slides, enhanced regulation of the digital images in shorter time span, and multiple magnification. The increasing use of digital pathology in academics, due to dynamic telepathology and real time imaging and controlled movement are expected to drive the digital pathology market in the coming years.
Based on the various products, the global digital pathology market can be broadly classified as scanners, analytics, storage, and communication or delivery modes. Based on the different application of digital pathology, the global digital pathology market can be segmented as human pathology (including Pharmaceutical & Biotechnology Companies, Training and Education and others), animal pathology (including pharmaceutical & biotechnology companies, academic & government research institutes, and contract research organizations).
The major driver for the growth of the digital pathology market includes worldwide growth in the prevalence of cancer, and cumulative use of companion diagnostics in the chronic diseases. Some of the other important drivers for the digital pathology market include the growing efficiency of the medical lab, and increasing clinical trials and drug development activities, around the globe.
The premium pricing of digital pathology is one of the major hindrances, in the widespread uses of digital pathology within the cost sensitive markets. Moreover, the stringent regulatory concern is also limiting the digital pathology market expansion. However the increasing use of digital pathology in biopharmaceuticals and drug toxicology is opening new market opportunities, for the digital pathology market.
North America accounted for the digital pathology market in 2014. The market dominance of North America is attributed to the presence of high adoption of advanced and sophisticated medical technology, in the region. It is then followed by Europe, with the large population of baby boomers, while the increasing trend towards companion diagnostics is one of the most dominant factors, driving the digital pathology market in this region. Asia-Pacific and Latin America are the fastest growing market for digital pathology, attributed to the increasing prevalence of cancer, in addition to the easy availability of consultation, enabled by digital pathology. Country wise, the U.S. and Canada are the largest market of digital pathology in North America. Germany, the U.K., France, and Italy are some of the major digital pathology markets in Europe. China, India, and Japan are the major digital pathology market in Asia-Pacific.
Some of the major players operating in the global digital pathology market include, 3dhistech Ltd., Aurora Interactive Ltd., Definiens AG, Hamamatsu Photonics K.K., Indica Labs Inc., Leica Biosystems Gmbh, Mikroscan Technologies Inc., Objective Pathology Services Ltd., Xifin Inc., Pixcelldata Ltd., Ventana Medical Systems Inc., Apollo Pacs Inc., Corista LLC, Digipath Inc., Huron Technologies International Inc., Kanteron Systems, Ligolab LLC , Nikon Instruments Inc., Omnyx LLC, Pathxl Ltd., Sunquest Information Systems Inc., and Visiopharm.